Genomic characterization of non-small-cell lung cancer in African Americans by targeted massively parallel sequencing

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1966-1973

  Araujo, Luiz H ^a   Timmers, Cynthia ^a   Bell, Erica Hlavin ^a   Shilo, Konstantin ^a   Lammers, Philip E ^c   Zhao, Weiqiang ^a   Natarajan, Thanemozhi G ^b   Miller, Clinton J ^b   Zhang, Jianying ^a   Yilmaz, Ayse S ^a   Liu, Tom ^a   Coombes, Kevin ^a   Amann, Joseph ^a   Carbone, David P ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b GenomOncology   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ARID1A PROTEIN, HUMAN; DNA HELICASE; NUCLEAR PROTEIN; SMARCA4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CHROMOSOME ARM; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; GENETIC CODE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASSIVELY PARALLEL SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; SMOKING; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CAUCASIAN; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION RATE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLUSTER ANALYSIS; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; DNA HELICASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION RATE; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; UNITED STATES;

EID: 84937128011     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.2444     Document Type: Article

References (46)

1. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075, 2008
2. Imielinski M, Berger AH, Hammerman PS, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107-1120, 2012
3. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525, 2012
4. Govindan R, Ding L, Griffith M, et al: Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121-1134, 2012
5. Seo JS, Ju YS, Lee WC, et al: The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22:2109-2119, 2012
6. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550, 2014
7. Jänne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23:3227-3234, 2005
8. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
9. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
10. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
11. Shi Y, Au JS, Thongprasert S, et al: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9:154-162, 2014
12. Bauml J, Mick R, Zhang Y, et al: Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist? Lung Cancer 81:347-353, 2013
13. Yamaguchi N, Vanderlaan PA, Folch E, et al: Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer 82:31-37, 2013
14. US Census Bureau: The Black Population: 2010. http://www.census.gov/prod/cen2010/briefs/c2010br-06.pdf
15. Ward E, Jemal A, Cokkinides V, et al: Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54:78-93, 2004
16. DeSantis C, Naishadham D, Jemal A: Cancer statistics for African Americans, 2013. CA Cancer J Clin 63:151-166, 2013
17. Phelps MA, Stinchcombe TE, Blachly JS, et al: Erlotinib in African Americans with advanced non-small cell lung cancer: A prospective randomized study with genetic and pharmacokinetic analyses. Clin Pharmacol Ther 96:182-191, 2014
18. Zakharia F, Basu A, Absher D, et al: Characterizing the admixed African ancestry of African Americans. Genome Biol 10:R141, 2009
19. Tang H, Jorgenson E, Gadde M, et al: Racial admixture and its impact on BMI and blood pressure in African and Mexican Americans. Hum Genet 119:624-633, 2006
20. Yaeger R, Avila-Bront A, Abdul K, et al: Comparing genetic ancestry and self-described race in African Americans born in the United States and in Africa. Cancer Epidemiol Biomarkers Prev 17:1329-1338, 2008
21. Bastos-Rodrigues L, Pimenta JR, Pena SD: The genetic structure of human populations studied through short insertion-deletion polymorphisms. Ann Hum Genet 70:658-665, 2006
22. Rosenberg NA, Pritchard JK, Weber JL, et al: Genetic structure of human populations. Science 298:2381-2385, 2002
23. Forbes SA, Tang G, Bindal N, et al: COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38:D652-D657, 2010
24. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 155:945-959, 2000
25. Buettner R, Wolf J, Thomas RK: Lessons learned from lung cancer genomics: The emerging concept of individualized diagnostics and treatment. J Clin Oncol 31:1858-1865, 2013
26. Mardis ER: A decade's perspective on DNA sequencing technology. Nature 470:198-203, 2011
27. Tran B, Dancey JE, Kamel-Reid S, et al: Cancer genomics: Technology, discovery, and translation. J Clin Oncol 30:647-660, 2012
28. Dias-Santagata D, Akhavanfard S, David SS, et al: Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146-158, 2010
29. MacConaill LE, Campbell CD, Kehoe SM, et al: Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887, 2009
30. Cote ML, Haddad R, Edwards DJ, et al: Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol 6:627-630, 2011
31. Leidner RS, Fu P, Clifford B, et al: Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer. J Clin Oncol 27:5620-5626, 2009
32. Yang SH, Mechanic LE, Yang P, et al: Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 11:2106-2110, 2005
33. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al: Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 15:5714-5723, 2009
34. Reinersman JM, Johnson ML, Riely GJ, et al: Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6:28-31, 2011
35. Rooney M, Devarakonda S, Govindan R: Genomics of squamous cell lung cancer. Oncologist 18:707-716, 2013
36. Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93, 2010
37. Wu JN, Roberts CW: ARID1A mutations in cancer: Another epigenetic tumor suppressor? Cancer Discov 3:35-43, 2013
38. Hoffman GR, Rahal R, Buxton F, et al: Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci USA111:3128-3133, 2014
39. Schneppenheim R, Frühwald MC, Gesk S, et al: Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86:279-284, 2010
40. Witkowski L, Carrot-Zhang J, Albrecht S, et al: Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 46:438-443, 2014
41. Jelinic P, Mueller JJ, Olvera N, et al: Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 46:424-426, 2014
42. Reisman D, Glaros S, Thompson EA: The SWI/SNF complex and cancer. Oncogene 28:1653-1668, 2009
43. Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10:4314-4324, 2004
44. Thompson KW, Marquez SB, Reisman D: A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1: Letter. Cancer Res 74:4946-4947, 2014
45. Oike T, Ogiwara H, Tominaga Y, et al: A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 73:5508-5518, 2013
46. Helming KC, Wang X, Wilson BG, et al: ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 20:251-254, 2014